Breaking Finance News

Roche Hldg (OTCMKTS:RHHBY) has been downgraded from Buy to Hold in a statement by Deutsche Bank earlier today.

Deutsche Bank has downgraded Roche Hldg (OTCMKTS:RHHBY) from Buy to Hold in a statement released on Friday July 07, 2017.

Having a price of $31.34, Roche Hldg (OTCMKTS:RHHBY) traded 0.06% higher on the day. With the last stock price down -1.50% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. RHHBY has recorded a 50-day average of $31.83 and a two hundred day average of $31.96. Trade Volume was down over the average, with 432,547 shares of RHHBY changing hands under the typical 1,669,710

Recent Performance Chart

Roche Hldg (OTCMKTS:RHHBY)

Roche Hldg has PE ratio of 21.59 with a one year low of $25.25 and a one year high of $36.82 and has a market capitalization of $0.

General Company Details For Roche Hldg (OTCMKTS:RHHBY)

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *